| Previous Close | 35.99 |
| Open | 36.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 35.91 - 36.19 |
| 52 Week Range | 29.83 - 36.21 |
| Volume | 15,731,081 |
| Avg. Volume | 17,361,603 |
| Market Cap | 213.93B |
| Beta | 1.06 |
| PE Ratio (TTM) | 26.31 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.61%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Reuters•3 hours ago
Versartis growth hormone drug fails key study, shares sink
Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent. The drug, somavaratan, ...
- Barrons.com•8 hours ago
[$$] Pfizer's Underappreciated Global Opportunity
Pfizer (PFE: NYSE) By Morgan Stanley ($35.45, Sept. 20) We are upgrading Pfizer stock from Equal-weight to Overweight and raising our price target from $35 to $39. This is a multiple call. Following underperformance, ...
- Market Realist•11 hours ago
These Key Pfizer Products Contributed to Growth in 2Q17
Pfizer's (PFE) key products contributing to growth include Eliquis, Ibrance, Lyrica, Xalkori, Xeljanz, and Xtandi.
